Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 135729-62-3] Palonosetronhydrochloride

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-A0021
Brand:	MCE
CAS:	135729-62-3

Overview

MDL	MFCD07370072
Molecular Weight	332.87
Molecular Formula	C19H25ClN2O
SMILES	O=C1N(C[C@@]([H])(CCC2)C3=C2C=CC=C13)[C@@H]4CN5CCC4CC5.[H]Cl

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.

Summary

Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). IC50 Value: Target: 5-HT Receptor Palonosetron is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy.

IC50 & Target

5-HT ₃ Receptor

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04912271	Fudan University	Chemotherapy-induced Nausea and Vomiting (CINV)	June 10, 2021	Phase 3
NCT00343460	Heron Therapeutics	Nausea and Vomiting\|Unspecified Adult Solid Tumor, Protocol Specific	June 2006	Phase 3
NCT00900757	Duke University\|Eisai Inc.	Malignant Glioma	August 2009	Phase 2
NCT02388750	Dr. Edward Chow\|Sunnybrook Health Sciences Centre	Nausea\|Vomiting	April 2015	Phase 2
NCT01481831	Shanghai Changzheng Hospital\|JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd	Neoplasms\|Chemotherapy-Induced Nausea and Vomiting	July 2011	Phase 4
NCT03040726	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Helsinn Healthcare SA	Malignant Neoplasm\|Nausea\|Vomiting	May 3, 2017	Phase 2\|Phase 3
NCT02941913	Instituto Nacional de Cancer, Brazil	Postoperative Nausea and Vomiting	October 2016	Phase 4
NCT01339260	Helsinn Healthcare SA\|Parexel	Chemotherapy-Induced Nausea and Vomiting	April 2011	Phase 3
NCT01909856	Jiangsu Simcere Pharmaceutical Co., Ltd.	Cancer	October 2011	Phase 2
NCT03008213	Joseph Ma\|University of California, San Diego	Chemotherapy Induced Nausea Vomiting	January 2017	Phase 2
NCT01952626	Kyungpook National University Hospital	Morphine Adverse Reaction	April 2013	Not Applicable
NCT01370408	Northside Hospital, Inc.\|Blood and Marrow Transplant Group of Georgia	Chemotherapy-induced Nausea and Vomiting	February 2012	Phase 2
NCT00600353	University of Kansas Medical Center\|Eisai Inc.	Myeloma, Plasma-Cell\|Lymphoma, Malignant	October 2007	Phase 2
NCT00410488	M.D. Anderson Cancer Center\|Eisai Inc.	Sarcoma\|Nausea\|Vomiting	December 2006	Not Applicable
NCT01395901	Helsinn Healthcare SA	Postoperative Nausea and Vomiting	June 2011	Phase 3
NCT04533867	Bagcilar Training and Research Hospital	Nausea, Postoperative\|Vomiting, Postoperative\|Patient Reported Outcomes\|Pain, Postoperative\|Antiemetics	August 15, 2020
NCT02445872	Zhejiang University\|Merck Sharp & Dohme LLC	Chemotherapy-Induced Nausea and Vomiting\|Lung Cancer	December 2015	Phase 2
NCT03586817	Hospital Federal de Bonsucesso	Nausea and Vomiting, Postoperative	March 2, 2019	Phase 4
NCT02541019	Hospital Federal de Bonsucesso	Postoperative Nausea and Vomiting	October 2015	Phase 4
NCT02468323	Hospital de Base	PONV	October 2015	Phase 4
NCT02809378	Ajou University School of Medicine\|HK inno.N Corporation	PONV\|Palonosetron\|Anesthesia	June 2016	Phase 4
NCT00415103	PETHEMA Foundation\|Merck Sharp & Dohme LLC	Leukemia\|Lymphoma	November 2006	Phase 4
NCT01482468	Incheon St.Mary´s Hospital	Postoperative Nausea and Vomiting	March 2012	Not Applicable
NCT01018758	Gruppo Italiano Studio Linfomi	Chemotherapy-Induced Nausea and Vomiting\|Non Hodgkin´s Lymphoma	July 2006	Phase 2
NCT03606369	Instituto Nacional de Cancerologia de Mexico	Breast Neoplasm\|Antineoplastic Agents\|Antiemetics\|Quality of Life	November 5, 2015	Phase 2\|Phase 3
NCT01442376	Helsinn Healthcare SA	Chemotherapy-Induced Nausea and Vomiting	September 2011	Phase 3
NCT01568268	Samsung Medical Center\|HK inno.N Corporation	Laparoscopic Gynecologic, Abdominal, Other Surgery\|General Anesthesia	January 2012	Phase 3
NCT00359567	Taiho Pharmaceutical Co., Ltd.	Chemotherapy-Induced Nausea and Vomiting	July 2006	Phase 3
NCT00306735	Eisai Inc.\|Helsinn Healthcare SA	Multiple Myeloma	March 2006	Phase 2
NCT04563260	Ajou University School of Medicine	Gallbladder Diseases	October 7, 2020	Not Applicable
NCT02970643	Hee Jun Kim\|HK inno.N Corporation\|Chung-Ang University Hosptial, Chung-Ang University College of Medicine	Chemotherapy-induced Nausea and Vomiting	July 2016	Not Applicable
NCT02205164	Associazione Salentina Angela Serra	Chemotherapy Induced Nausea and Vomiting	October 2011	Phase 2
NCT03960151	Costantine Albany\|Tesaro, Inc.\|Hoosier Cancer Research Network	Germ Cell Tumor	May 2018	Phase 2
NCT01640340	Ohio State University Comprehensive Cancer Center	Malignant Neoplasm	January 2011	Not Applicable
NCT00952133	NYU Langone Health\|Eisai Inc.	PONV	July 2009	Phase 4
NCT02597907	Kyungpook National University Hospital	Postoperative Nausea and Vomiting	July 2014	Not Applicable
NCT02557035	Helsinn Healthcare SA\|PSI CRO	Chemotherapy-Induced Nausea and Vomiting	October 2015	Phase 3
NCT04507711	Seoul National University Bundang Hospital	Blood Coagulation Disorder	September 16, 2020	Not Applicable
NCT03148704	Cttq	Palonosetron	March 8, 2017
NCT00895245	University of Washington\|National Cancer Institute (NCI)	Nausea and Vomiting\|Stage III Squamous Cell Carcinoma of the Hypopharynx\|Stage III Squamous Cell Carcinoma of the Larynx\|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage III Squamous Cell Carcinoma of the Nasopharynx\|Stage III Squamous Cell Carcinoma of the Oropharynx\|Stage IV Squamous Cell Carcinoma of the Hypopharynx\|Stage IV Squamous Cell Carcinoma of the Larynx\|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage IV Squamous Cell Carcinoma of the Nasopharynx\|Stage IV Squamous Cell Carcinoma of the Oropharynx	February 2009	Phase 2
NCT00666783	Xijing Hospital	Chemotherapy-Induced Nausea and Vomiting		Phase 2
NCT01478165	Incheon St.Mary´s Hospital	Postoperative Nausea and Vomiting	September 2011	Not Applicable
NCT04592198	Xiamen LP Pharmaceutical Co., Ltd	Nausea With Vomiting Chemotherapy-Induced	October 1, 2020	Phase 2
NCT03578081	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Malignant Neoplasm	October 15, 2018	Phase 3
NCT00828295	Helsinn Healthcare SA	Postoperative Nausea and Vomiting	August 2008	Phase 3
NCT03674294	Sun Yat-sen University	Gastrointestinal Neoplasms\|Chemotherapy-induced Nausea and Vomiting	August 4, 2015	Phase 3
NCT00412425	M.D. Anderson Cancer Center\|Eisai Inc.	Melanoma	November 2006	Phase 1\|Phase 2
NCT05199818	Xiamen LP Pharmaceutical Co., Ltd	Chemotherapy-induced Nausea and Vomiting	March 1, 2022	Phase 3
NCT02625181	Vanderbilt University\|Vanderbilt University Medical Center	Postoperative Nausea and Vomiting	July 2016	Not Applicable
NCT00687011	Merck Sharp & Dohme LLC	Neoplasms\|Nausea\|Vomiting	October 10, 2006	Phase 4
NCT02744508	Yonsei University	Orthopedic Surgery	July 24, 2015	Not Applicable
NCT01650961	Seoul National University Hospital	Anesthesia, General\|Palonosetron	July 2012	Not Applicable
NCT00661674	Stanford University	Substance-Related Disorders	April 2008	Not Applicable
NCT01376297	Helsinn Healthcare SA\|Parexel	Chemotherapy-Induced Nausea and Vomiting	July 2011	Phase 3
NCT04060771	Universidade Federal Fluminense	Anesthesia\|Strabismus\|PONV	August 1, 2018	Phase 3
NCT00381862	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Colorectal Cancer\|Nausea and Vomiting	June 2006	Phase 2
NCT01031498	M.D. Anderson Cancer Center\|Eisai Inc.	Acute Myelogenous Leukemia\|Chemotherapy-induced Nausea and Vomiting	September 2005	Phase 2
NCT01825733	Yonsei University	Postoperative Nausea and Vomiting	August 2011	Not Applicable
NCT02484911	First Affiliated Hospital of Harbin Medical University\|Harbin Medical University	Chemotherapy-induced Nausea and Vomiting	May 2015	Phase 3
NCT03204279	Helsinn Healthcare SA	Chemotherapy-induced Nausea and Vomiting (CINV)	August 31, 2017	Phase 2
NCT00553059	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Solvay Pharmaceuticals	Chemotherapy-induced Nausea and Vomiting\|Unspecified Adult Solid Tumor, Protocol Specific	May 2008	Phase 3
NCT04576390	Theodor Bilharz Research Institute\|Cairo University	Antiemetic\|Postoperative Nausea and Vomiting	October 24, 2020	Phase 4
NCT04308837	Icahn School of Medicine at Mount Sinai	Gastric Cancer\|Stomach Cancer	July 31, 2018	Phase 2
NCT00475085	Joseph Roscoe\|National Cancer Institute (NCI)\|University of Rochester	Nausea	December 2006	Phase 3
NCT02650479	Intarcia Therapeutics	Healthy Adult Male and Female Volunteers	January 2016	Phase 1
NCT01046240	Clinica Universidad de Navarra, Universidad de Navarra	Emesis	October 2009	Phase 1\|Phase 2
NCT00982995	University of Michigan Rogel Cancer Center	Nausea\|Vomiting\|Terminally Ill	November 2010	Phase 2
NCT03649230	Purdue Pharma, Canada	Chemotherapy-Induced Nausea and Vomiting	October 3, 2018
NCT00684463	Merck Sharp & Dohme LLC	Neoplasms\|Nausea\|Vomiting	April 11, 2007	Phase 4
NCT00636805	Duke University\|Eisai Inc.\|National Institute of Neurological Disorders and Stroke (NINDS)	Brain Cancer	May 2008	Phase 2
NCT00343863	University of Washington\|National Cancer Institute (NCI)	Male Breast Cancer\|Nausea and Vomiting\|Stage I Breast Cancer\|Stage II Breast Cancer\|Stage IIIA Breast Cancer	January 2006	Not Applicable
NCT03097588	OHSU Knight Cancer Institute\|Helsinn Therapeutics (U.S.), Inc\|Oregon Health and Science University	Malignant Neoplasm	April 27, 2017	Phase 2
NCT02203253	China Medical University, China\|The First Hospital of Liaoning Medical University\|The First Affiliated Hospital of Dalian Medical University\|The Second Affiliated Hospital of Dalian Medical University\|Liaoning Tumor Hospital & Institute\|Shengjing Hospital\|General Hospital of Shenyang Military Region\|Liaoyang Central Hospital\|Third People´s hospital Liaoyang\|Petrochemical General Hospital of Liaoyang city\|Anshan Tumor Hospital	Neoplasms	July 2014	Phase 3
NCT00967499	Eisai Inc.	Postoperative Nausea and Vomiting	July 13, 2009	Phase 2
NCT02135510	Amsterdam UMC, location VUmc\|Noordwest Ziekenhuisgroep\|Rijnstate\|Tergooiziekenhuizen locatie Hilversum\|Ziekenhuis Amstelland	Solid Tumors	June 2013	Phase 3
NCT03403712	Helsinn Healthcare SA\|George Clinical Pty Ltd\|The Physicians´ Services Incorporated Foundation	Chemotherapy-induced Nausea and Vomiting	March 16, 2018	Phase 3
NCT03817970	University of Colorado, Denver\|Memorial Sloan Kettering Cancer Center\|Rutgers University\|National Institute of General Medical Sciences (NIGMS)	Nephrotoxicity	June 26, 2019	Not Applicable
NCT01476280	Incheon St.Mary´s Hospital	Postoperative Nausea and Vomiting	May 2011	Not Applicable
NCT00903396	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Anal Cancer\|Carcinoma of the Appendix\|Colorectal Cancer\|Extrahepatic Bile Duct Cancer\|Gallbladder Cancer\|Gastric Cancer\|Gastrointestinal Carcinoid Tumor\|Liver Cancer\|Nausea and Vomiting\|Pancreatic Cancer\|Primary Peritoneal Cavity Cancer\|Small Intestine Cancer	September 2009	Phase 2
NCT01169805	Yonsei University	Laparoscopic Marsupialization of Renal Cyst	August 2010	Not Applicable
NCT00503386	Hangzhou Jiuyuan Gene Engineering Co. Ltd.,\|Sun Yat-sen University\|Tigermed Consulting Co., Ltd	Nausea\|Vomiting\|Chemotherapy	April 2006	Phase 2
NCT01363479	Helsinn Healthcare SA\|Parexel	Chemotherapy-Induced Nausea and Vomiting	July 2011	Phase 3
NCT04585412	Yung Shin Pharm. Ind. Co., Ltd.	Chemotherapy-induced Nausea and Vomiting, Prophylaxis	August 17, 2020	Phase 4
NCT03933605	Yeungnam University College of Medicine	Postoperative Nausea\|Postoperative Vomiting	July 10, 2017	Not Applicable
NCT02480088	Yonsei University	Postoperative Nausea and Vomiting	September 22, 2014	Phase 4
NCT05315999	Gerhild Becker\|University Hospital Freiburg	Nausea\|Vomiting\|Pain\|Advanced Cancer	May 2022	Phase 2
NCT02635828	Ohio State University\|Eisai Inc.	Postoperative Nausea and Vomiting	October 2009	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 300.42 mM ; Need ultrasonic)

DMSO : 3.33 mg/mL ( 10.00 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0042 mL	15.0209 mL	30.0418 mL
5 mM	0.6008 mL	3.0042 mL	6.0084 mL
10 mM	0.3004 mL	1.5021 mL	3.0042 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (300.42 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Vishnu Murthy M, Srinivas K, Kumar R, Mukkanti K. Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthalethyl stationary phase. J Pharm Bio
[2] Ajioka H, Morita F, Akizawa Y, Yoshida K, Kitamura R, Takimoto H. Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist.Nihon Yakurigaku Zasshi. 2
[3] Ruhlmann C, Herrstedt J. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2010 Feb;10(2):137-48.
[4] Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. Am J Health Syst Pharm. 2007 Jun 1;64(11):1209-13.
[5] Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglen, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al.2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformati

Synonyms

1H-Benz[de]isoquinolin-1-one, 2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-, hydrochloride (1:1), (3aS)-

1H-Benz[de]isoquinolin-1-one, 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-, monohydrochloride, [S-(R*,R*)]-

1H-Benz[de]isoquinolin-1-one, 2-(3S)-1-azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-, monohydrochloride, (3aS)-

RS 25259-197

Palonosetron hydrochloride

Aloxi

Onicit

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart